Alnylam Pharmaceuticals' Cost of Revenue rose 140.58% to $197.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $512.1 million, marking a year-over-year increase of 85.65%. This contributed to the annual value of $306.5 million for FY2024, which is 14.28% up from last year.
According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Cost of Revenue is $197.2 million, which was up 38.87% from $142.0 million recorded in Q2 2025.
In the past 5 years, Alnylam Pharmaceuticals' Cost of Revenue registered a high of $197.2 million during Q3 2025, and its lowest value of $23.0 million during Q1 2021.
Over the past 3 years, Alnylam Pharmaceuticals' median Cost of Revenue value was $75.3 million (recorded in 2023), while the average stood at $89.5 million.
In the last 5 years, Alnylam Pharmaceuticals' Cost of Revenue fell by 10.71% in 2024 and then surged by 140.58% in 2025.
Alnylam Pharmaceuticals' Cost of Revenue (Quarterly) stood at $33.6 million in 2021, then soared by 37.27% to $46.2 million in 2022, then skyrocketed by 55.88% to $72.0 million in 2023, then spiked by 42.62% to $102.6 million in 2024, then spiked by 140.58% to $197.2 million in 2025.
Its Cost of Revenue was $197.2 million in Q3 2025, compared to $142.0 million in Q2 2025 and $70.2 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value